Adjuvant role of macrophages in stem cell-induced cardiac repair in rats |
Lim, Soo yeon
(Cell Regeneration Research Center, Chonnam National University Hospital)
Cho, Dong Im (Cell Regeneration Research Center, Chonnam National University Hospital) Jeong, Hye-yun (Cell Regeneration Research Center, Chonnam National University Hospital) Kang, Hye-jin (Cell Regeneration Research Center, Chonnam National University Hospital) Kim, Mi Ra (Cell Regeneration Research Center, Chonnam National University Hospital) Cho, Meeyoung (Cell Regeneration Research Center, Chonnam National University Hospital) Kim, Yong Sook (Cell Regeneration Research Center, Chonnam National University Hospital) Ahn, Youngkeun (Cell Regeneration Research Center, Chonnam National University Hospital) |
1 | Pandey, A. C., Lancaster, J. J., Harris, D. T., Goldman, S. & Juneman, E. Cellular therapeutics for heart failure: focus on mesenchymal stem cells. Stem Cells Int. 2017, 640108 (2017). |
2 | Nguyen, P. K., Rhee, J. W. & Wu, J. C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1, 831-841 (2016). DOI |
3 | Bolli, R. et al. Rationale and design of the CONCERT-HF trial (Combination of Mesenchymal and c-kit(+) cardiac stem cells as regenerative therapy for heart failure. Circ. Res. 122, 1703-1715 (2018). DOI |
4 | Medzhitov, R. & Horng, T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9, 692-703 (2009). DOI |
5 | Fraccarollo, D., Galuppo, P. & Bauersachs, J. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc. Res. 94, 293-303 (2012). DOI |
6 | Harel-Adar, T. et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc. Natl Acad. Sci. USA 108, 1827-1832 (2011). DOI |
7 | Birge, R. B. et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 23, 962-978 (2016). DOI |
8 | Frantz, S. et al. Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J. 27, 871-881 (2013). DOI |
9 | van Amerongen, M. J., Harmsen, M. C., van Rooijen, N., Petersen, A. H. & van Luyn, M. J. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am. J. Pathol. 170, 818-829 (2007). DOI |
10 | de Couto, G. et al. Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J. Clin. Invest. 125, 3147-3162 (2015). DOI |
11 | Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42-49 (2009). DOI |
12 | Powell, R. J. et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol. Ther. 20, 1280-1286 (2012). DOI |
13 | Ledford, K. J., Zeigler, F. & Bartel, R. L. Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res. Ther. 4, 134 (2013). DOI |
14 | Ledford, K. J., Murphy, N., Zeigler, F. & Bartel, R. L. Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases. Stem Cell Res. Ther. 4, 135 (2013). DOI |
15 | Henry, T. D. et al. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ. Res. 115, 730-737 (2014). DOI |
16 | Patel, A. N. et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 387, 2412-2421 (2016). DOI |
17 | Ericson, J. A. et al. Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. PLoS ONE 9, e108553 (2014). DOI |
18 | Courties, G. et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63, 1556-1566 (2014). DOI |
19 | Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231-238 (2011). DOI |
20 | Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005). DOI |
21 | Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999). DOI |
22 | Choudry, F. et al. A randomized double-blind control study of early intracoronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trialdagger. Eur. Heart J. 37, 256-263 (2016). DOI |
23 | Cho, D. I. et al. The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction. Oncotarget 8, 44281-44294 (2017). |
24 | Hahn, J. Y. et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol. 51, 933-943 (2008). DOI |
25 | Hare, J. M. et al. Comparison of allogeneic vs autologous bone marrowderived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308, 2369-2379 (2012). DOI |
26 | Nauta, A. J. & Fibbe, W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506 (2007). |
27 | Ben-Mordechai, T. et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J. Am. Coll. Cardiol. 62, 1890-1901 (2013). DOI |
28 | Hu, X. et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 135, 799-808 (2008). DOI |
29 | Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037-3047 (2007). DOI |
30 | Leblond, A. L. et al. Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction. PLoS ONE 10, e0137515 (2015). DOI |
31 | Jeong, H. Y. et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci. Rep. 5, 15768 (2015). DOI |
32 | Cho, D. I. et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp. Mol. Med. 46, e70 (2014). DOI |
33 | Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002). DOI |
34 | Han, J. et al. Dual Roles of Graphene Oxide To Attenuate Inflammation and Elicit Timely Polarization of Macrophage Phenotypes for Cardiac Repair. ACS Nano 12, 1959-1977 (2018). DOI |
35 | Sager, H. B. et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ. Res. 119, 853-864 (2016). DOI |
36 | Heidt, T. et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ. Res. 115, 284-295 (2014). DOI |
37 | Sano, T. et al. Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease. Circ. Res. 122, 994-1005 (2018). DOI |
38 | Lee, S. J. et al. Enhanced therapeutic and long-term dynamic vascularization effects of human pluripotent stem cell-derived endothelial cells encapsulated in a nanomatrix gel. Circulation 136, 1939-1954 (2017). DOI |
![]() |